#USA #Trevi Therapeutics #Haduvio #chronic cough #New Haven, Connecticut

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a biopharmaceutical company currently in the clinical stage, focused on creating effective therapies for chronic cough conditions. This August, Trevi is set to participate in two major biotech conferences in the United States, showcasing its innovative approach to treatment.

Conference Details

Oppenheimer's 2025 Biotech in the Berkshires

Date: August 4 – 6, 2025
Location: Berkshires, Massachusetts
Representative: Jennifer Good, President and CEO

Stifel's 2025 Biotech Summer Summit

Date: August 11 – 13, 2025
Location: Newport, Rhode Island
Fireside Chat Date: August 11, at 1:00 p.m. ET
Representatives: Jennifer Good, President and CEO; Farrell Simon, Pharm.D., Chief Commercial Officer

At these conferences, Trevi will discuss its investigational therapy, Haduvio™ (oral nalbuphine ER), which is designed specifically to address the challenges associated with chronic cough due to idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is noted for being the first investigational therapy to demonstrate a statistically significant decrease in cough frequency among patients with these conditions during clinical trials.

Chronic cough is a widespread issue, affecting around 85% of people suffering from IPF, with approximately 150,000 diagnosed in the U.S. alone. Patients can experience the distressing symptom of coughing up to 1,500 times a day, which not only exacerbates existing health issues but also severely impacts their social and mental well-being. Unfortunately, there are no currently approved therapies for treating chronic cough specifically in IPF patients, and existing off-label treatments yield insufficient benefits.

In addition, refractory chronic cough—characterized as a cough that persists for over 8 weeks despite treatment for underlying conditions—has no approved treatments in the U.S. This condition affects between 2 and 3 million individuals, emphasizing the urgent need for effective solutions that can improve quality of life for those affected.

Trevi's proposed new therapy, Haduvio, is positioned as a potential breakthrough. It works by acting on the cough reflex arc in both central and peripheral pathways, utilizing its unique mechanism as a kappa agonist and mu antagonist (KAMA). This dual action specifically targets opioid receptors that are pivotal in controlling chronic cough.

However, it is essential to note that nalbuphine, the active ingredient in Haduvio, is not currently classified by the U.S. Drug Enforcement Agency, simplifying its regulatory pathway.

As Trevi prepares for these significant events, the company aims to raise awareness of its promising therapy, Haduvio, and its potential to alleviate the burdens of chronic cough. You can find additional information about Trevi Therapeutics and updates on their initiatives by visiting their website or following their social media channels.

For media inquiries or further information, individuals are encouraged to reach out to Trevi’s representative contacts provided in their latest announcements.

Conclusion

Trevi Therapeutics is making strides in the biopharmaceutical field with its innovative therapy that could transform the treatment landscape for patients suffering from chronic cough conditions. By participating in key industry conferences, Trevi is poised to enhance visibility for its advancements and engage with healthcare professionals about its ongoing clinical developments.